Fundraising Fox
Tenax Therapeutics
NASDAQ: TENXChapel Hill, US · Delaware corporation · 1 known investors
Find your way into Tenax Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
607 people can intro you to Tim
Ask Diane Goostree to introduce you to Tim Healey
You →Diane · together at Marion Laboratories →Tim
369 people can intro you to Chris
Ask Jamie Chen to introduce you to Chris Giordano
You →Jamie · together at PPD →Chris
224 people can intro you to So-Young
Ask Sam Okafor to introduce you to So-Young Kim
You →Sam · together at Bayer →So-Young
- Lawrence R. Hoffman45 people can intro you
Sign up to find every way you can get introduced to Tenax Therapeutics
- Your email: who you already know at Tenax Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tenax Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
Founders & leadership
SR
Stuart RichChief Medical Officer
LR
Lawrence R. HoffmanInterim Chief Financial OfficerLawrence R. Hoffman is a CPA and attorney with a Master of Laws in Taxation who brings extensive financial and legal experience in life sciences and contract research organizations. He has held senior financial roles at The Liposome Company, Averion International, and Sybron Chemicals, and has experience in M&A, IPOs, and SEC reporting.
MB
Michael B. JebsenExecutive
CG
Chris GiordanoPresident and Chief Executive OfficerChris Giordano has spent more than two decades in clinical pharmaceutical development, holding leadership roles including President of Novella Clinical (later acquired into IQVIA) where he oversaw expansion of a clinical trial portfolio and integration of EU-based firms, and previously serving as Global Head of Cardiovascular, Renal and Metabolic Therapeutic Area at Quintiles, where he managed large-scale clinical trials in cardiology, immunology, and metabolic disease. He is now President and Chief Executive Officer of Tenax Therapeutics.
TH
Tim HealeyChief Commercial OfficerTim Healey is Chief Commercial Officer at Tenax Therapeutics and has held commercial leadership roles at EVERSANA, Lantheus, Abbott Laboratories/AbbVie, and AMAG Pharmaceuticals, with experience in product launches across primary care, specialty, and rare disease markets. He holds a B.S. from Boston College and an M.B.A. from Babson College.
SK
So-Young KimExecutive Vice President of Clinical Development and StrategySo-Young Kim has over two decades of pharmaceutical industry experience spanning research, development, and commercialization, with specialist training in internal medicine and cardiology. She previously held senior leadership positions at Bayer AG overseeing strategic direction of a large pharmaceutical portfolio, and currently serves as Executive Vice President of Clinical Development and Strategy at Tenax Therapeutics.
GP
Gregory PepinNamed on SEC filing
JM
James MitchumNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$123.2M disclosed across 5 of 6 rounds · 1900–2024
▶$99.7MraisedAug 2024 · 24 investors · PharmaceuticalsRule 506(b)
▶$99.7MraisedAug 2024 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael DavidsonDirector
- Stuart RichExecutive Officer, Director
- Lawrence R. HoffmanExecutive Officer
- Christopher T. GiordanoExecutive Officer, Director
- Declan DooganDirector
- June AlmenoffDirector
- Robyn M. HunterDirector
- Gerald T. ProehlDirector
- Offering amount
- $175M
- Amount sold
- $99.7M
- Sales commissions
- $6.8M
- Placement agents
- Leerink Partners LLC, Guggenheim Securities, LLC, Roth Capital Partners, LLC, William Blair & Company, L.L.C.
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedJun 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedJun 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith MaherDirector
- Robyn HunterDirector
- Michael DavidsonDirector
- Christopher T. GiordanoExecutive Officer, Director
- Steven BoydDirector
- Declan DooganDirector
- Eliot LurierExecutive Officer
- Gerald ProehlDirector
- June AlmenoffDirector
- Stuart RichExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MraisedJul 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael JebsenExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $750K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$5.2MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael B. JebsenExecutive Officer
- James MitchumDirector
- Chris A. RallisDirector
- Ronald R. BlanckDirector
- Gerald ProehlDirector
- Gregory PepinDirector
- Anthony DiTonnoDirector, Executive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- Sales commissions
- $1.4M
- Placement agents
- H.C. Wainwright & Co., LLC, Ladenburg Thalmann & Co. Inc.
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$317.2KraisedMar 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$317.2KraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael B. JebsenExecutive Officer
- Ronald R. BlanckDirector
- Gregory PepinDirector
- James MitchumDirector
- Chris A. RallisDirector
- Gerald ProehlDirector
- Anthony DiTonnoDirector, Executive Officer
- Offering amount
- $317.2K
- Amount sold
- $317.2K
- Sales commissions
- $206K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Tonix Pharmaceuticals HoldingTonix is a biotechnology company developing therapies for chronic and complex conditions across central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. Its pipeline includes candidates for acute stress disorder, PTSD, smallpox/mpox vaccination, organ transplant rejection, and Prader-Willi syndrome.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as Tenax Therapeutics.
Frequently asked questions
- What does Tenax Therapeutics do?
- Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
- Who are Tenax Therapeutics's investors?
- Tenax Therapeutics's investors include Vivo Capital.
- How much funding has Tenax Therapeutics raised?
- Tenax Therapeutics has disclosed $123.2M raised across 5 of its 6 known rounds.
- Where is Tenax Therapeutics headquartered?
- Tenax Therapeutics is headquartered in Chapel Hill, US.